Effects of losartan treatment on the physicochemical properties of diabetic rat bone

Donmez B. Ö., Unal M., ÖZDEMİR S., Ozturk N., OĞUZ N., Akkus O.

JOURNAL OF BONE AND MINERAL METABOLISM, cilt.35, sa.2, ss.161-170, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s00774-016-0748-9
  • Dergi Adı: JOURNAL OF BONE AND MINERAL METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.161-170
  • Anahtar Kelimeler: Bone, Losartan, Diabetes mellitus, Osteopenia, Renin-angiotensin system, RENIN-ANGIOTENSIN SYSTEM, COLLAGEN CROSS-LINKS, CONVERTING ENZYME-INHIBITOR, AGE-RELATED-CHANGES, MINERAL DENSITY, FRACTURE RISK, CANCELLOUS BONE, HIP FRACTURE, OSTEOPOROSIS, MELLITUS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Inhibitors of the renin-angiotensin system used to treat several diseases have also been shown to be effective on bone tissue, suggesting that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce fracture risk. The present study investigated the effects of losartan on the physicochemical and biomechanical properties of diabetic rat bone. Losartan (5 mg/kg/day) was administered via oral gavage for 12 weeks. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry. Whole femurs were tested under tension to evaluate the biomechanical properties of bone. The physicochemical properties of bone were analyzed by Fourier transform infrared spectroscopy. Although losartan did not recover decreases in the BMD of diabetic bone, it recovered the physicochemical (mineral and collagen matrix) properties of diabetic rat bone. Furthermore, losartan also recovered ultimate tensile strength of diabetic rat femurs. Losartan, an angiotensin II type 1 receptor blocker, has a therapeutic effect on the physicochemical properties of diabetic bone resulting in improvement of bone strength at the material level. Therefore, specific inhibition of this pathway at the receptor level shows potential as a therapeutic target for diabetic patients suffering from bone diseases such as osteopenia.